SRRM1 coordinates an alternative splicing program that promotes expression of oncogenic protein isoforms.

This study identifies SRRM1 as a key splicing regulator that, often in concert with SRSF11, drives the expression of oncogenic protein isoforms—including those of NUMB and other signaling or cytoskeletal genes—to promote tumor growth, proliferation, and stemness in multiple cancer types, thereby highlighting its potential as a therapeutic target.

The Gist

Imagine your body's cells are like a massive, bustling construction site. To build a house (a healthy cell), you need a blueprint. In our bodies, that blueprint is DNA. But here's the twist: the blueprint isn't just one single instruction manual; it's a giant book of instructions where you can choose different chapters to build different versions of the same room.

This process is called Alternative Splicing. It's like a master editor who can cut and paste sentences in the blueprint to create different versions of a protein. Sometimes, the editor makes a "Good Version" that keeps the cell healthy. Other times, a glitchy editor makes a "Bad Version" that turns the cell into a cancerous monster.

The Story of the "Glitchy Editor"

This paper is about discovering who the "glitchy editors" are in the world of cancer, specifically focusing on a protein called NUMB.

1. The Crime Scene: The NUMB Protein
Think of the NUMB protein as a security guard for the cell. Its job is to stop the cell from growing out of control. However, NUMB has two faces:

• The Good Guard (Short Version): This version skips a specific page (Exon 9) in the blueprint. It does its job well and keeps the cell safe.
• The Bad Guard (Long Version): This version includes that extra page (Exon 9). When this happens, the guard gets confused and actually helps the cell grow uncontrollably, leading to cancer.

In many cancers (like colon, lung, and breast cancer), the cell is stuck making the "Bad Guard" version. The scientists wanted to know: Who is forcing the editor to include that extra page?

2. The Detective Work: The CRISPR Search
The researchers set up a massive "Wanted" poster. They created a special cell line that glows Green if it makes the Good Guard and Red if it makes the Bad Guard.

• They then used a genetic "scissors" tool (CRISPR) to cut out thousands of different genes, one by one, to see which one, when removed, stopped the cell from glowing Red.
• It's like turning off the lights in a dark room one by one to see which switch controls the red alarm.

The Result: They found two main culprits: SRRM1 and SRSF11. These are the "Boss Editors" that force the cell to include the dangerous extra page in the NUMB blueprint.

3. The Smoking Gun: A Whole Network of Trouble
The scientists didn't stop at just NUMB. They realized these two "Boss Editors" aren't just messing with one blueprint; they are hacking the entire construction site.

• They found that SRRM1 and SRSF11 also mess with blueprints for other proteins involved in cell movement, cell division, and stem cells.
• The Analogy: Imagine SRRM1 is a corrupt foreman. He doesn't just change the instructions for the security guard; he also changes the instructions for the cranes, the bricklayers, and the power generators, making the whole construction site chaotic and prone to building illegal, dangerous structures (tumors).

4. The Consequences: What Happens When You Fire the Boss?
The team tested what happens if they remove SRRM1 from cancer cells.

• The Effect: The cancer cells stopped growing. They couldn't form colonies (like a gang of criminals couldn't set up a base). They couldn't move or invade other areas.
• The Mechanism: Without SRRM1, the cells went back to making the "Good Guard" (short NUMB) and stopped making the "Bad Guard." They also stopped making other dangerous proteins that help cancer spread.
• The Metaphor: It's like firing the corrupt foreman. Suddenly, the construction crew stops building illegal skyscrapers and starts building safe, stable houses again. The cancer cells lose their "superpowers" to grow and spread.

Why This Matters

This paper is a big deal because it identifies SRRM1 as a potential target for new cancer drugs.

• Current Chemo: Often acts like a sledgehammer, smashing everything (good and bad cells) in the construction site.
• Future Therapy: If we can develop a drug that specifically targets and disables SRRM1, we could act like a precise sniper. We could stop the "Bad Editors" from making the cancerous blueprints without hurting the healthy cells.

In a Nutshell:
Cancer often happens because the cell's "editing software" gets hacked to produce dangerous protein versions. This study found the specific "hackers" (SRRM1 and SRSF11) responsible for this in several major cancers. By understanding how they work, we might be able to fix the software, stop the cancer from growing, and give the body's natural defenses a fighting chance.

Technical Summary

1. Problem Statement

Alternative splicing (AS) is a critical mechanism for generating proteomic diversity, but its dysregulation is a hallmark of cancer. Specifically, the NUMB gene undergoes developmentally regulated alternative splicing of exon 9 (E9). In stem cells and progenitors, E9 is included (producing p71/p72 isoforms), while in differentiated cells, it is skipped (producing p65/p66). In many cancers, this regulation is reversed, leading to the overexpression of E9-included isoforms which promote oncogenesis, stemness, and metastasis. While the functional consequences of NUMB E9 dysregulation are known, the specific splicing factors driving this aberrant splicing in cancer contexts (particularly those distinct from developmental regulation) remain poorly understood. Identifying these regulators is essential for developing therapeutic strategies to correct pathological splicing.

2. Methodology

The authors employed a multi-faceted approach combining genome-wide screening, molecular biology, and bioinformatics:

• Dual-Fluorescent Splicing Reporter: They constructed a mini-gene reporter where NUMB exons 8–10 (including introns) were cloned upstream of EGFP and mCherry. A +2 bp frameshift mutation in E9 ensured that E9 inclusion produced EGFP, while E9 skipping produced mCherry.
• Genome-Wide CRISPR-Cas9 Screen:
  • An inducible DLD1 (colorectal cancer) cell line expressing the reporter was generated.
  • Cells were transduced with the TKOv3 pooled sgRNA library (targeting ~18,000 genes).
  • After 9 days, cells were sorted via FACS to isolate populations with high EGFP/low mCherry (E9 inclusion) and low EGFP/high mCherry (E9 skipping).
  • sgRNA enrichment was analyzed via NGS to identify genes whose knockout altered splicing.
• Validation & Mechanistic Studies:
  • siRNA/shRNA Knockdown: Validated hits (SRRM1, SRSF11, DDX23) in multiple cell lines (DLD1, HCT116, A549, MDA-MB-468, HEK293) using RT-qPCR and semi-quantitative PCR to assess endogenous NUMB E9 splicing.
  • Affinity Purification Mass Spectrometry (AP-MS): Used Flag-tagged SRRM1 and SRSF11 to map protein-protein interactomes in DLD1 and HEK293 cells.
  • Bulk RNA-Seq: Performed on SRRM1 and SRSF11 silenced DLD1 cells to identify global changes in alternative splicing (ASEs) and gene expression (DEGs).
• Clinical Correlation:
  • Compared RNA-seq data from knockdown experiments with The Cancer Genome Atlas (TCGA) data (COAD, BRCA, LUAD, LUSC) to identify splicing events that are both regulated by these factors and dysregulated in human tumors.
• Phenotypic Assays: Colony formation, proliferation, wound healing, and invasion assays were conducted on inducible shRNA cell lines to assess the functional impact of SRRM1 loss.

3. Key Contributions

• Identification of Novel Regulators: The study identifies SRRM1 (Serine/Arginine Repetitive Matrix 1) and SRSF11 as critical, previously under-characterized regulators of NUMB E9 inclusion in cancer.
• Definition of a Coordinated Splicing Program: The authors demonstrate that SRRM1 and SRSF11 do not act in isolation but coordinate a broad oncogenic splicing program affecting genes involved in signaling, cytoskeleton dynamics, and transcription.
• Link to RAS Signaling: The findings suggest a mechanistic link between activated RAS signaling (present in the DLD1 screen model) and the dysregulation of SRRM1-mediated splicing, providing a potential pathway for oncogenic splicing reversion.
• Therapeutic Target Validation: The study establishes SRRM1 as a potential therapeutic target, showing that its loss impairs multiple malignant phenotypes.

4. Key Results

A. Discovery of SRRM1 and SRSF11

• The CRISPR screen identified SRRM1 and SRSF11 as top hits promoting NUMB E9 inclusion. Knockdown of these factors caused significant E9 skipping (reverting to the tumor-suppressive isoform).
• Interactome Analysis: SRRM1 and SRSF11 share a common interactome enriched for RNA binding proteins, core spliceosome components (U1, U2, Tri-snRNP), and the Exon Junction Complex (EJC). They also interact with m6A methylation factors, suggesting a link between splicing and RNA modification.

B. Global Splicing Landscape

• RNA-seq Analysis: SRRM1 silencing altered 712 ASEs, while SRSF11 altered 1,214. There was a 94% concordance in the directionality of splicing changes for the 166 common targets.
• Oncogenic Targets: Beyond NUMB, SRRM1/SRSF11 regulate splicing events in genes critical for cancer hallmarks:
  • MKNK2: Promotes the oncogenic MKNK2B isoform (exon 14a skipping) over the tumor-suppressive MKNK2A. Knockdown restores MKNK2A, activating p38 stress response.
  • TBX3 & FOXM1: Promote inclusion of exons (TBX3 exon 2a, FOXM1 exon 6) associated with stemness and proliferation. Knockdown reduces these oncogenic isoforms.
  • KAT5: Promotes the skipping of exon 5 (dominant-negative isoform). Knockdown restores the tumor-suppressive full-length KAT5.
  • ECT2 & DIAPH1: Regulate splicing events linked to Rho GTPase signaling and cell migration.
  • PTBP1: Regulates its own splicing, creating a feedback loop.

C. Clinical Relevance

• Analysis of TCGA data revealed that the splicing shifts induced by SRRM1 knockdown (e.g., exon inclusion in NUMB, TBX3, FOXM1) closely mirror the patterns observed in tumor tissues compared to normal tissues across colorectal, lung, and breast cancers.

D. Phenotypic Consequences of SRRM1 Loss

• Cellular Phenotypes: SRRM1 knockdown significantly reduced cell proliferation, colony formation, migration, and invasion in colorectal and lung cancer cells.
• Gene Expression Changes: Loss of SRRM1 led to the downregulation of key oncogenic drivers (Cyclin D1, PRDX2, NOTUM) and upregulation of tumor suppressors (CDKN2B).
• Mechanism: The reduction in proliferation is partly mediated by the restoration of MKNK2A (activating p38) and the downregulation of transcription factors (FOXM1, TBX3, TCF7L2) that drive the expression of cell cycle and EMT genes.

5. Significance

This study provides a comprehensive map of how specific splicing factors drive oncogenesis through a coordinated program rather than isolated events.

• Mechanistic Insight: It elucidates how SRRM1 acts as a "splicing node" that integrates signals (potentially from RAS pathways) to rewire the proteome toward a malignant state by promoting embryonic/stem-like isoforms (e.g., NUMB E9, TBX3 2a).
• Therapeutic Potential: SRRM1 is highlighted as a promising therapeutic target. Inhibiting SRRM1 could simultaneously reverse multiple oncogenic splicing events, restore tumor-suppressive isoforms (like MKNK2A and KAT5), and suppress Wnt signaling and cell proliferation.
• Biomarker Potential: Given the correlation between SRRM1 levels and aggressive tumor phenotypes, SRRM1 could serve as a biomarker for high-risk cancers or a target for splicing-modulating therapies.

In conclusion, the paper establishes SRRM1 as a master regulator of a cancer-specific splicing program that sustains malignancy, offering a new avenue for targeting the "splicing code" in cancer therapy.